ArticleRespirology case reports2026
Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long-Term Treatment With the Janus Kinase 1-Selective Inhibitor, Filgotinib: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Knowledge Regarding the Epidemiology, Exacerbating Factors, and Treatment of Rheumatoid Arthritis Complicated by Interstitial Lung Disease.Journal of clinical medicine · 2026Review
- Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long-Term Treatment With the Janus Kinase 1-Selective Inhibitor, Filgotinib: A Case Report.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA). A 68-year-old man had dyspnea, decreased forced vital capacity, and elevated Krebs von den Lungen-6 levels. Non-specific interstitial pneumonia-like patterns, including ground-glass opacities, fibrosis, and subpleural spared area, were observed on computed tomography. Both rheumatoid factor and anti-cyclic citrullinated peptide antibody were positive; however, he had no clinical evidence of arthritis. Two years later, he developed arthritis, which was diagnosed as RA with high disease activity. He was started on salazosulfapyridine, which had no effect on the arthritis. Filgotinib, a selective Janus kinase (JAK) 1 inhibitor, was added for arthritis treatment; thereafter, the ILD improved alongside the arthritis. He maintained remission for 4 years with no exacerbation, flare, or adverse events. JAK1 inhibitor may be safe and beneficial in the long-term control and treatment of arthritis and ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.